Di Brizzi EV, Caccavale S, Di Caprio R, Cusano F, De Pasquale R, Falcomatà V, et al. Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?. Dermatol Pract Concept [Internet]. 2024 Oct. 30 [cited 2025 Mar. 16];14(4):e2024284. Available from: https://www.dpcj.org/index.php/dpc/article/view/4769